Glutamate and Dopamine in Schizophrenia: an Update for the 21st Century

Overview

Journal J Psychopharmacol

Publisher Sage Publications

Specialty Pharmacology

Date 2015 Jan 15

PMID 25586400

Citations 303

Authors

Oliver Howes

Rob McCutcheon

James Stone

Affiliations

Soon will be listed here.

Abstract

The glutamate and dopamine hypotheses are leading theories of the pathoaetiology of schizophrenia. Both were initially based on indirect evidence from pharmacological studies supported by post-mortem findings, but have since been substantially advanced by new lines of evidence from in vivo imaging studies. This review provides an update on the latest findings on dopamine and glutamate abnormalities in schizophrenia, focusing on in vivo neuroimaging studies in patients and clinical high-risk groups, and considers their implications for understanding the biology and treatment of schizophrenia. These findings have refined both the dopamine and glutamate hypotheses, enabling greater anatomical and functional specificity, and have been complemented by preclinical evidence showing how the risk factors for schizophrenia impact on the dopamine and glutamate systems. The implications of this new evidence for understanding the development and treatment of schizophrenia are considered, and the gaps in current knowledge highlighted. Finally, the evidence for an integrated model of the interactions between the glutamate and dopamine systems is reviewed, and future directions discussed.

Citing Articles

Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.

Kumar U Int J Mol Sci. 2025; 26(1.

PMID: 39796008 PMC: 11720483. DOI: 10.3390/ijms26010152.

Advancement in utilization of magnetic resonance imaging and biomarkers in the understanding of schizophrenia.

Tirpack A, Buttar D, Kaur M World J Clin Cases. 2025; 13(1):96578.

PMID: 39764531 PMC: 11577517. DOI: 10.12998/wjcc.v13.i1.96578.

Gene-level analysis reveals the genetic aetiology and therapeutic targets of schizophrenia.

Dang X, Teng Z, Yang Y, Li W, Liu J, Hui L Nat Hum Behav. 2025; .

PMID: 39753749 DOI: 10.1038/s41562-024-02091-4.

Identification of serum metabolic traits of AIWG in first-episode schizophrenia patients.

Zhang S, Zhai Z, Gao T, Kuai X, Li X, Dong Y BMC Psychiatry. 2024; 24(1):946.

PMID: 39716136 PMC: 11667919. DOI: 10.1186/s12888-024-06413-8.

Effects of Sarcosine (N-methylglycine) on NMDA (N-methyl-D-aspartate) Receptor Hypofunction Induced by MK801: In Vivo Calcium Imaging in the CA1 Region of the Dorsal Hippocampus.

Hsiao Y, Chang C, Lee T, Liao W, Lai W, Chang F Brain Sci. 2024; 14(11).

PMID: 39595913 PMC: 11592077. DOI: 10.3390/brainsci14111150.

References

Lieberman J, Kane J, Alvir J . Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl). 1987; 91(4):415-33. DOI: 10.1007/BF00216006. View

Kegeles L, Abi-Dargham A, Zea-Ponce Y, Mann J, van Heertum R, Cooper T . Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry. 2000; 48(7):627-40. DOI: 10.1016/s0006-3223(00)00976-8. View

Homayoun H, Moghaddam B . NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007; 27(43):11496-500. PMC: 2954603. DOI: 10.1523/JNEUROSCI.2213-07.2007. View

CAMPDEN-MAIN B, WEGIELSKI Z . The control of deviant behavior in chronically disturbed psychotic patients by the oral administration of reserpine. Ann N Y Acad Sci. 1955; 61(1):117-22. DOI: 10.1111/j.1749-6632.1955.tb42458.x. View

Vernaleken I, Klomp M, Moeller O, Raptis M, Nagels A, Rosch F . Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability. Int J Neuropsychopharmacol. 2012; 16(4):745-54. DOI: 10.1017/S1461145712000764. View

Pitcher G, Kalia L, Ng D, Goodfellow N, Yee K, Lambe E . Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. Nat Med. 2011; 17(4):470-8. PMC: 3264662. DOI: 10.1038/nm.2315. View

Balla A, Sershen H, Serra M, Koneru R, Javitt D . Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release. Neuropsychopharmacology. 2002; 28(1):34-44. DOI: 10.1038/sj.npp.1300019. View

Malmberg A, Jackson D, Eriksson A, Mohell N . Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol. 1993; 43(5):749-54. View

Hirvonen J, van Erp T, Huttunen J, Aalto S, Nagren K, Huttunen M . Brain dopamine d1 receptors in twins discordant for schizophrenia. Am J Psychiatry. 2006; 163(10):1747-53. DOI: 10.1176/ajp.2006.163.10.1747. View

10.

Mortimer A, Singh P, Shepherd C, Puthiryackal J . Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Clin Schizophr Relat Psychoses. 2010; 4(1):49-55. DOI: 10.3371/CSRP.4.1.4. View

11.

Perry T . Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett. 1982; 28(1):81-5. DOI: 10.1016/0304-3940(82)90212-9. View

12.

Whiteford H, Degenhardt L, Rehm J, Baxter A, Ferrari A, Erskine H . Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013; 382(9904):1575-86. DOI: 10.1016/S0140-6736(13)61611-6. View

13.

Aalto S, Hirvonen J, Kajander J, Scheinin H, Nagren K, Vilkman H . Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology (Berl). 2002; 164(4):401-6. DOI: 10.1007/s00213-002-1236-6. View

14.

Jablensky A . Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci. 2001; 250(6):274-85. DOI: 10.1007/s004060070002. View

15.

Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B . Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014; 153(1-3):169-76. DOI: 10.1016/j.schres.2014.01.011. View

16.

Fusar-Poli P, Howes O, Valmaggia L, McGuire P . 'Truman' signs and vulnerability to psychosis. Br J Psychiatry. 2008; 193(2):168. DOI: 10.1192/bjp.193.2.168. View

17.

Deakin J, Lees J, McKie S, Hallak J, Williams S, Dursun S . Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry. 2008; 65(2):154-64. DOI: 10.1001/archgenpsychiatry.2007.37. View

18.

ARNOLD A, Freeman H . Reserpine in hospitalized psychotics; a controlled study on chronically disturbed women. AMA Arch Neurol Psychiatry. 1956; 76(3):281-5. DOI: 10.1001/archneurpsyc.1956.02330270053012. View

19.

Bartha R, Williamson P, Drost D, Malla A, Carr T, Cortese L . Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1997; 54(10):959-65. DOI: 10.1001/archpsyc.1997.01830220085012. View

20.

Goto N, Yoshimura R, Kakeda S, Nishimura J, Moriya J, Hayashi K . Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatr Dis Treat. 2012; 8:119-22. PMC: 3333782. DOI: 10.2147/NDT.S25582. View